Literature DB >> 27909132

Myxofibrosarcoma of the extremity and trunk: a multidisciplinary approach leads to good local rates of LOCAL control.

C G Ghazala1, N R Agni1, M Ragbir1, P Dildey1, D Lee1, K S Rankin2, T B Beckingsale1, C H Gerrand1.   

Abstract

AIMS: Myxofibrosarcomas (MFSs) are malignant soft-tissue sarcomas characteristically presenting as painless slowly growing masses in the extremities. Locally infiltrative growth means that the risk of local recurrence is high. We reviewed our experience to make recommendations about resection strategies and the role of the multidisciplinary team in the management of these tumours. PATIENTS AND METHODS: Patients with a primary or recurrent MFS who were treated surgically in our unit between 1997 and 2012 were included in the study. Clinical records and imaging were reviewed. A total of 50 patients with a median age of 68.4 years (interquartile range 61.6 to 81.8) were included. There were 35 men; 49 underwent surgery in our unit.
RESULTS: The lower limb was the most common site (32/50, 64%). The mean size of the tumours was 8.95 cm (1.5 to 27.0); 26 (52%) were French Fédération Nationale des Centres de Lutte Contre le Cancer grade III. A total of 21 (43%) had positive margins after the initial excision; 11 underwent further excision. Histology showed microscopic spread of up to 29 mm beyond macroscopic tumour. Local recurrence occurred in seven patients (14%) at a mean of 21 months (3 to 33) and 15 (30%) developed metastases at a mean of 17 months (3 to 30) post-operatively.
CONCLUSION: High rates of positive margins and the need for further excision makes this tumour particularly suited to management by multidisciplinary surgical teams. Microscopic tumour can be present up to 29 mm from the macroscopic tumour in fascially-based tumours. Cite this article: Bone Joint J 2016;98-B:1682-8. ©2016 The British Editorial Society of Bone & Joint Surgery.

Entities:  

Keywords:  Local recurrence; Margins; Multidisciplinary; Myxofibrosarcoma; Surgery

Mesh:

Year:  2016        PMID: 27909132     DOI: 10.1302/0301-620X.98B12.37568

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  8 in total

Review 1.  Extremity Soft Tissue Sarcoma: Role of Local Control.

Authors:  Elyse J Brinkmann; Safia K Ahmed; Matthew T Houdek
Journal:  Curr Treat Options Oncol       Date:  2020-02-05

Review 2.  Diagnosis and Management of Subcutaneous Soft Tissue Sarcoma.

Authors:  Makoto Endo; Nokitaka Setsu; Toshifumi Fujiwara; Takeaki Ishii; Makoto Nakagawa; Kenichiro Yahiro; Atsushi Kimura; Eijiro Shimada; Yasuharu Nakashima; Yoshihiro Matsumoto
Journal:  Curr Treat Options Oncol       Date:  2019-05-25

3.  Synovial sarcoma of the elbow presenting with painful stiffness: a case report.

Authors:  Jennifer L Nevin; Graham Jw King
Journal:  Shoulder Elbow       Date:  2020-11-26

4.  Oncological Outcomes in Patients with Appendicular Myxofibrosarcomas: A Retrospective Study.

Authors:  Yonghoon Lee; Michael P Guertin; Spencer Summers; Sheila A Conway; Mothasem Al Maaieh; Raphael Yechieli; Jonathan Trent; Andrew E Rosenberg; Juan Pretell-Mazzini
Journal:  J Oncol       Date:  2021-11-28       Impact factor: 4.375

5.  Analysis of prognostic factors in 171 patients with myxofibrosarcoma of the trunk and extremities: a cohort study.

Authors:  Huanmei Liu; Xinxin Zhang; Shuguang Zhang; Shengji Yu
Journal:  Ann Transl Med       Date:  2021-08

6.  High Recurrence Rate of Myxofibrosarcoma: The Effect of Radiotherapy Is Not Clear.

Authors:  Hjalmar Teurneau; Jacob Engellau; Iman Ghanei; Fredrik Vult von Steyern; Emelie Styring
Journal:  Sarcoma       Date:  2019-10-01

Review 7.  Soft tissue tumours of the elbow: current concepts.

Authors:  Olga D Savvidou; Panagiotis Koutsouradis; Ioanna K Bolia; Angelos Kaspiris; George D Chloros; Panayiotis J Papagelopoulos
Journal:  EFORT Open Rev       Date:  2020-01-28

8.  Development and validation of a prognostic nomogram for predicting the overall survival of myxofibrosarcoma patients: a large population-based study.

Authors:  Shuai Cao; Jie Li; Jun Zhang; Haopeng Li
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.